ITRM
MaterialsIterum Therapeutics plc Ordinary Share
Live · NASDAQ · May 8, Close
What's Moving ITRM Today?
No stock-specific AI insight has been generated for ITRM yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
ITRM News
20 articles- Iterum Therapeutics plc (NASDAQ:ITRM): Are Analysts Optimistic?Yahoo Finance·Apr 1, 2026
- Iterum Therapeutics Announces Filing of Winding Up PetitionYahoo Finance·Mar 27, 2026
- Iterum Therapeutics Provides Business UpdateYahoo Finance·Feb 13, 2026
- Iterum Therapeutics PLC (ITRM) Q3 2025 Earnings Call Highlights: Launch Success and Financial ...Yahoo Finance·Nov 14, 2025
- Iterum Therapeutics Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 14, 2025
- Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025Yahoo Finance·Nov 7, 2025
- Analysts Expect Breakeven For Iterum Therapeutics plc (NASDAQ:ITRM) Before LongYahoo Finance·Oct 17, 2025
- Iterum Therapeutics to Present Data at IDWeek 2025Yahoo Finance·Oct 14, 2025
- Iterum Therapeutics sees cash runway into 2026Yahoo Finance·Sep 20, 2025
- Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.Yahoo Finance·Aug 20, 2025
- Iterum Therapeutics Reports Second Quarter 2025 Financial ResultsYahoo Finance·Aug 5, 2025
- Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025Yahoo Finance·Jul 29, 2025
- Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jul 2, 2025
- Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial GrowthYahoo Finance·Jun 30, 2025
- Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM EvidenceYahoo Finance·Jun 25, 2025
- Iterum Therapeutics Announces Partnership for Commercialization ServicesYahoo Finance·Jun 11, 2025
- Iterum Therapeutics Announces Extension of Term of Promissory NoteYahoo Finance·May 19, 2025
- Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ...Yahoo Finance·May 14, 2025
- Iterum Therapeutics Reports First Quarter 2025 Financial ResultsYahoo Finance·May 13, 2025
- Iterum Therapeutics plc (NASDAQ:ITRM): When Will It Breakeven?Yahoo Finance·May 10, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Iterum Therapeutics plc Ordinary Share
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.